Home
/
NOVAVAX INC
/
Financials
/
Quarterly
NOVAVAX INC — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that NOVAVAX INC filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$70.45M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$239.24M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$666.66M
May 8, 2025
Q3
2025
Sep 30, 2024
$84.51M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$415.48M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$93.86M
May 8, 2025
Q3
2024
Sep 30, 2023
$186.99M
Nov 12, 2024
Q2
2024
Jun 30, 2023
$424.43M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$80.95M
May 10, 2024
Q3
2023
Sep 30, 2022
$734.58M
Nov 9, 2023
Q2
2023
Jun 30, 2022
$185.93M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$703.97M
May 9, 2023
Q3
2022
Sep 30, 2021
$178.84M
Nov 9, 2022
Q2
2022
Jun 30, 2021
$298.02M
Aug 9, 2022
Q1
2022
Mar 31, 2021
$447.23M
May 10, 2022
Q3
2021
Sep 30, 2020
$157.02M
Nov 5, 2021
Q2
2021
Jun 30, 2020
$35.54M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$3.38M
May 10, 2021
Q3
2020
Sep 30, 2019
$2.51M
Nov 10, 2020
Q2
2020
Jun 30, 2019
$3.36M
Aug 10, 2020
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$70.45M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$239.24M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$666.46M
May 8, 2025
Q3
2025
Sep 30, 2024
$84.51M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$415.48M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$93.86M
May 8, 2025
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($202.38M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
$106.51M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$518.65M
May 8, 2025
Q3
2025
Sep 30, 2024
($121.30M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
$162.38M
Aug 6, 2025
Q1
2025
Mar 31, 2024
($147.55M)
May 8, 2025
Q3
2024
Sep 30, 2023
($130.78M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
$58.01M
Aug 8, 2024
Q1
2024
Mar 31, 2023
($293.91M)
May 10, 2024
Q3
2023
Sep 30, 2022
($168.61M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($510.49M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
$203.41M
May 9, 2023
Q3
2022
Sep 30, 2021
($322.43M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($352.32M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($222.72M)
May 10, 2022
Q3
2021
Sep 30, 2020
($197.31M)
Nov 5, 2021
Q2
2021
Jun 30, 2020
($17.52M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($25.86M)
May 10, 2021
Q3
2020
Sep 30, 2019
($18.04M)
Nov 10, 2020
Q2
2020
Jun 30, 2019
($39.60M)
Aug 10, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($178.02M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
$101.07M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$515.51M
May 8, 2025
Q3
2025
Sep 30, 2024
($134.02M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
$161.00M
Aug 6, 2025
Q1
2025
Mar 31, 2024
($144.83M)
May 8, 2025
Q3
2024
Sep 30, 2023
($125.63M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
$55.46M
Aug 8, 2024
Q1
2024
Mar 31, 2023
($312.77M)
May 10, 2024
Q3
2023
Sep 30, 2022
($127.19M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($482.96M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
$209.29M
May 9, 2023
Q3
2022
Sep 30, 2021
($307.14M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($345.83M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($208.63M)
May 10, 2022
Q3
2021
Sep 30, 2020
($193.94M)
Nov 5, 2021
Q2
2021
Jun 30, 2020
($17.03M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($22.90M)
May 10, 2021
Q3
2020
Sep 30, 2019
($14.99M)
Nov 10, 2020
Q2
2020
Jun 30, 2019
($36.67M)
Aug 10, 2020